#Cardiomegaly is most similar to cardiac

[manojkhanal-neurologist]

How Are Multiple Sclerosis and Atherosclerosis Similar?

Multiple sclerosis (MS) and atherosclerosis are two different medical conditions, but they share some surprising similarities. While MS affects the nervous system and atherosclerosis impacts the blood vessels, both involve the immune system, inflammation, and long-term health effects. Understanding these similarities can help individuals recognize the importance of early diagnosis and proper medical care.

What is Multiple Sclerosis?

Common Symptoms of MS:

Muscle weakness or spasms

Fatigue

Numbness or tingling in the limbs

Difficulty walking or maintaining balance

Vision problems

Cognitive difficulties (memory issues, trouble concentrating)

Patients experiencing frequent headaches should consult a Headache Specialist Doctor in Delhi for proper diagnosis and management.

What is Atherosclerosis?

Atherosclerosis is a condition in which the arteries become narrowed and hardened due to the buildup of fatty deposits (plaques). This condition can restrict blood flow and lead to serious complications like heart attacks and strokes.

Common Symptoms of Atherosclerosis:

Chest pain or discomfort (angina)

Shortness of breath

Weakness in the limbs

High blood pressure

Stroke symptoms (slurred speech, loss of balance, sudden weakness)

People at risk of stroke should seek immediate care from a Brain Stroke Doctor in Delhi to prevent complications.

Similarities Between MS and Atherosclerosis

Although MS and atherosclerosis affect different parts of the body, they share key characteristics:

1. Chronic Conditions

Both diseases are long-term and progress over time. They require ongoing medical care and lifestyle adjustments to manage symptoms and slow progression.

2. Inflammation Plays a Major Role

In both conditions, inflammation is a primary cause of damage:

In MS, inflammation leads to the destruction of myelin, affecting nerve function.

In atherosclerosis, inflammation contributes to plaque buildup, narrowing arteries and increasing the risk of heart disease.

3. Immune System Dysfunction

Both conditions involve the immune system attacking the body:

MS is an autoimmune disease where the immune system attacks nerve fibers.

In atherosclerosis, immune cells contribute to plaque formation and artery damage.

4. Increased Risk of Neurological Problems

MS directly affects the nervous system, but atherosclerosis can also impact brain health. Reduced blood flow from atherosclerosis can lead to strokes and cognitive issues, similar to MS symptoms.

Patients experiencing frequent migraines should consult a Migraine Specialist Doctor in Shalimar Bagh to explore treatment options.

Key Differences Between MS and Atherosclerosis

Despite their similarities, MS and atherosclerosis have key differences:

Cause: MS is an autoimmune disease, while atherosclerosis is caused by plaque buildup in the arteries.

Affected Systems: MS affects the nervous system, while atherosclerosis primarily affects the cardiovascular system.

Symptoms: MS leads to muscle weakness and coordination problems, while atherosclerosis primarily affects heart health and blood flow.

Managing and Treating These Conditions

Multiple Sclerosis Treatment

Disease-modifying therapies (DMTs)

Physical therapy and exercise

Managing stress and maintaining a healthy diet

Consulting a Headache Specialist Doctor in Delhi for symptom relief

Atherosclerosis Treatment

Lifestyle changes (healthy diet, exercise, quitting smoking)

Medications to lower cholesterol and blood pressure

Surgery in severe cases (angioplasty, bypass surgery)

Seeking care from an Epilepsy Specialists Doctor in Shalimar Bagh if neurological symptoms arise

Conclusion

While multiple sclerosis and atherosclerosis are distinct conditions, they share common factors such as chronic inflammation, immune system involvement, and the potential for neurological symptoms. Early diagnosis and proper treatment from specialists like a Epilepsy Specialists Doctor in Shalimar Bagh or an Epilepsy treatment Clinic in Shalimar Bagh can help patients manage their conditions effectively. If you experience symptoms related to either condition, consult a healthcare professional for guidance and treatment options.

[ketshubhra]

Transthyretin (TTR) Amyloidosis Market | by Disease Type, Treatment, Gender, End User, and Region

Industry Research Report – Transthyretin (TTR) Amyloidosis Market forecast till 2023, is latest research report published by MRFR. The Global TTR Amyloidosis Market is segmented on the basis of treatment, gender, end-user, disease type, and Region.

Transthyretin (TTR) Amyloidosis Market Overview

The Transthyretin (TTR) amyloidosis market is likely to register a robust growth over the forecast period. Transthyretin (TTR) amyloidosis is a health condition characterized by anomalous deposits of a protein named amyloid (amyloidosis) in a person's tissues and organs. It usually affects autonomic neuropathy or peripheral neuropathic system and cardiac system. Amyloidosis symptoms are often ambiguous having similarity to symptoms caused by other conditions. The symptoms vary based on the location and type of the amyloid deposits. Primarily, three major types of transthyretin amyloidosis have been identified. The neuropathic type of transthyretin amyloidosis affects the autonomic and peripheral nervous systems, resulting in trouble controlling bodily functions and peripheral neuropathy. The leptomeningeal type of transthyretin amyloidosis mostly affects the central nervous system. The cardiac type of Transthyretin (TTR) amyloidosis puts patients at the risk of orthostatic hypertension, cardiomegaly, and arrhythmia.

Get a FREE Sample with Complete TOC By considering the COVID-19 impact on market @ https://www.marketresearchfuture.com/sample_request/6155

The surging African American population, increasing number of ATTR therapeutic drug launches, increasing average income of individuals, and growing healthcare awareness among people serves as key factors for driving the Transthyretin (TTR) amyloidosis market growth.

However, progress of the market can be restricted by strict governing policies, incorrect diagnosis of TTR ailments, restraints on clinical trials, and high cost of TTR drugs. Unavailability of advanced diagnostic methods in the middle-income nations and lack of knowledge about Transthyretin amyloidosis acts as major challenges to the market.

Transthyretin (TTR) Amyloidosis Market Segmentation

The worldwide Transthyretin (TTR) amyloidosis market has been segmented based on treatment, gender, end-user, and disease type. Based on treatment, the market has been segmented into organ transplantation, RNAi therapy, small molecules treatment, and others. Small molecules treatment has been sub-segmented as diflunisal and tafamidis. Based on gender, the market has been segmented into male and female. Based on end-user, the market has been segmented into ambulatory surgical centers, hospitals and clinics, and others. Based on disease type, the market has been segmented into Transthyretin (TTR) familial amyloid polyneuropathy, Transthyretin (TTR) familial amyloid cardiomyopathy, and others.

Transthyretin (TTR) Amyloidosis Market Regional Analysis

The Americas hold the largest market share for Transthyretin (TTR) amyloidosis. The growth is owing to the rising occurrence of amyloidosis among adults and older population and increasing elderly population. For instance, a report published by ASCO Journal in 2016 stated that almost 4,000 people suffered from amyloidosis each year in the United States. Additionally, increasing government funding, technologically advanced diagnostic equipment, and surging research initiatives in advanced medical treatment options are likely to drive the market. The existence of leading pharmaceutical brands such as Merck and Pfizer also boost the market in this region.

Europe represents the second largest share in the global Transthyretin (TTR) amyloidosis market. The Europe market has been anticipated to grow remarkably over the forecast period. The growth is owing to soaring healthcare expenditure, availability of progressive treatment facilities, amplifying demand for improved healthcare infrastructure collectively with government initiatives for healthcare reform. In the U.K., almost 60 new cases of Transthyretin (TTR) amyloidosis are reported every year. Furthermore, increased affordability coupled with well-established medical device manufacturers accelerate the market to a great extent. However, increasing incidences of wrong diagnosis and the inefficiency of treatment procedures are likely to restrict the growth in the Europe market.

Asia Pacific market has been fast expanding owing to rising aged population. Moreover, increasing patient pool, government initiatives to enhance the healthcare facility, availability of favorable insurance reimbursement policies, and a rapid adoption of advanced technology are likely to stimulate the Transthyretin (TTR) amyloidosis market.

The Middle East and Africa market has been anticipated to register least growth owing to limited access to treatment facilities and lack of health awareness. In the Middle East, Saudi Arabia and the United Arab Emirates are the largest markets. The market growth has been attributed to the easy accessibility of specialty care centers and growth of healthcare industry. However, the market is expected to witness steady development due to the genetical predisposition of Africans for transthyretin amyloidosis and administrative initiatives to excel the quality of healthcare in the region.

Transthyretin (TTR) Amyloidosis Market Key Players

The global Transthyretin (TTR) amyloidosis market has been dominated by key players such as Pfizer, Alnylam Pharmaceuticals, Ionis Pharmaceuticals Inc., Arcturus Therapeutics, Corino Therapeutics Inc, and Proclara Bioscience.

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/transthyretin-amyloidosis-market-6155 

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com

NOTE: Our team of researchers are studying Covid-19 and its impact on various industry verticals and wherever required we will be considering covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.